Drug General Information (ID: DDINH08DXM)
Drug Name			Lanreotide		Drug Info		Ertugliflozin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Somatostatin/Somatostatin Analogs				Antidiabetic Agents
Structure

Mechanism of Lanreotide-Ertugliflozin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Lanreotide				Ertugliflozin
Mechanism 1		Hypoglycemic effects				Antidiabetic agent
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Lanreotide and Ertugliflozin
Antagonize the effect of antihypertensive agents Click to Show/Hide Mechanism Graph
Drug Name		Lanreotide				Ertugliflozin
Mechanism 2		Hyperglycemia				Antidiabetic agent
Key Mechanism Factor 2
		Factor Name		Antihypertensive agents
		Factor Description		The hypotensive effect of antihypertensive agents may be reduced, leading to higher blood pressure, increased blood pressure fluctuations, and possible cardiovascular damage.
Mechanism Description		Antagonize the effect of Ertugliflozin when combined with Lanreotide
Mechanism 3		Hyperglycemic effects				Antidiabetic agent
Key Mechanism Factor 3
		Factor Name		Antihypertensive agents
		Factor Description		The hypotensive effect of antihypertensive agents may be reduced, leading to higher blood pressure, increased blood pressure fluctuations, and possible cardiovascular damage.
Mechanism Description		Antagonize the effect of Ertugliflozin when combined with Lanreotide

Recommended Action
Management		Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.

References
1	Product Information. Sandostatin (octreotide). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
2	Product Information. Somatuline Depot (lanreotide). Ipsen Inc, Milford, MA.
3	Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR "Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin diabetes mellitus." Horm Metab Res 20 (1988): 168-70. [PMID: 2898427]